iiinova — where your digital self keeps evolving

Craig Gedye @craiggedye.bsky.social · 28/06/2026

Sunday at #ANZUP #ASM26 here in beautiful Adelaide starts with the Perfect Pitch, Trial Coordinators Session and ANZUP/PCFA Nurses Session. But first, coffee and thanks to Icon for supporting this essential kick-start! @anzuptrials.bsky.social @iconcancercentre.bsky.social #PCFA

000

Craig Gedye @craiggedye.bsky.social · 19/06/2026

People that confuse correlation with causation need to drink 8 glasses of water per day during hydration breaks xkcd.com/3260/

000

Craig Gedye @craiggedye.bsky.social · 18/06/2026

On World Kidney Cancer Day, it's incredible to reflect what progress has been made, but how much there is still to go. This recent paper shows what we might be possible if every person with advanced #kidneycancer could experience a complete response to immunotherapy www.ejcancer.com/article/S095...

From Andersen et al., Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC
Clinical outcomes of RCC responders and multivariable analysis. A-C) Kaplan-Meier curves for PFS (A), OS (B) and DSS (C) in RCC responders stratified by depth of response. 95% CI are reported in parentheses. D–F) Forest plots from multivariable Cox proportional hazards models showing HRs (log scale) and 95% CIs for selected clinical covariates associated with PFS (D), OS (E), and DSS (F).

010

Craig Gedye @craiggedye.bsky.social · 30/05/2026

Thank you once again to 347 Australians with #glioblastoma, 28 hospitals, over 70 Consortium members, the NHMRC CTC, and COGNO as we present the MAGMA trial at #ASCO #ASM26

030

Craig Gedye @craiggedye.bsky.social · 30/11/2025

The kids have (sadly) aged out of Lego advent calendars, so thanks again to @FreseniusKabi for shipping their IV saline in such strong and repurposable cardboard boxes!

030

Craig Gedye @craiggedye.bsky.social · 25/11/2025

Grateful to have overheard a colleague talking about "preemptive pregabilin". Offered immediate upfront pregabilin for a patient with florid and painful shingles, with rapid improvement of pain. No prospective trials but interesting case series. 10/10 would Rx again. journals.lww.com/ejanaesthesi...

130

Craig Gedye @craiggedye.bsky.social · 25/11/2025

Our goal for every person, every day xkcd.com/3172/

xkcd.com

Fifteen Years

020

Reposted by Craig Gedye

Fumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 20/11/2025

"Beyond respectful language, which is the minimum requirement… [this study] reinforces the broader message about maintaining respect for patients as individuals & ensuring that this is reflected in our words & deeds." @ascocancer.bsky.social @jco-asco.bsky.social @ethicsdoctorp.bsky.social

ascopubs.org

Don't Do Me Like That: Promoting Respectful Language in Oncology Research | JCO Oncology Practice

152

Craig Gedye @craiggedye.bsky.social · 19/10/2025

When life gives you sour mandarins...

020

Craig Gedye @craiggedye.bsky.social · 16/09/2025

Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!

141

Craig Gedye @craiggedye.bsky.social · 04/09/2025

Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team

153

Reposted by Craig Gedye

Peter van Galen @vangalenlab.bsky.social · 15/08/2025

Online today! *Aging, Immune Fitness and Cancer* 🔬 Learn the latest about the intersection between these processes in @natrevcancer.nature.com 🧬 Great to work with @sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...

0167

Craig Gedye @craiggedye.bsky.social · 02/08/2025

One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...

youtube.com

The Whitlams - Blow Up The Pokies (Official Video)

YouTube video by thewhitlamsofficial

030

Craig Gedye @craiggedye.bsky.social · 30/07/2025

Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.

020

Reposted by Craig Gedye

ANZUP Cancer Trials Group @anzuptrials.bsky.social · 28/07/2025

The Renal IGW is fast approaching. Concept submissions close in 1 week! Register your attendance here anzup.org.au/idea-generat... @craiggedye.bsky.social

042

Reposted by Craig Gedye

Ian Davis @profiand.bsky.social · 26/07/2025

Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.

242

Reposted by Craig Gedye

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social

042

Craig Gedye @craiggedye.bsky.social · 23/06/2025

Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!

000

Reposted by Craig Gedye

Soragni:Lab @alice.soragnilab.com · 03/06/2025

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies www.nature.com/articles/s41...

nature.com

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

13414

Reposted by Craig Gedye

Prof Haryana Dhillon @hagsie.bsky.social · 02/06/2025

Meet Cherrie, one of the earliest participants in the CHALLENGE trial, and my colleague Janette Vardy talking about what these results mean. www.9news.com.au/videos/natio...

9news.com.au

9News - Latest news and headlines from Australia and the world

Latest news and headlines from Australia and the world

021

Reposted by Craig Gedye

Aaron Mitchell @thewonkologist.bsky.social · 31/05/2025

Presenting at #ASCO25 today! I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not. Cc @dusetzinas.bsky.social

54118

Craig Gedye @craiggedye.bsky.social · 09/05/2025

#Teletrials in action: a generous and kind participant called me this week for Visit #3 of his participation in @anzuptrials.bsky.social #ANZadapt #clinicaltrial. “Where are you?”, I asked. “Let me send you a photo”, he said. How’s the serenity…

130

Reposted by Craig Gedye

European Medicines Agency @ema.europa.eu · 16/04/2025

🚨 Public consultations now open: help shape how medicine information is shared with patients. We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients. 🔗 Learn more & share your input: europa.eu/!TCm47q

02922

Reposted by Craig Gedye

International Kidney Cancer Coalition @ikccorg.bsky.social · 06/04/2025

Excellent, thought-provoking presentation by Deb Maskens of IKCC on the % of patients that are not being reached by #KidneyCancer organisations and strategies to consider on how we can improve. #IKCC25 @debmaskens.bsky.social

031

Craig Gedye @craiggedye.bsky.social · 27/03/2025

Great piece from Lancet Global Health on democratising clinical trials research to strengthen primary healthcare, relevant to ALL healthcare. Every healthcare intervention is a clinical trial of n = 1; why not learn from every patient, every clinician?

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00513-8/fulltext

000

Reposted by Craig Gedye

Quentin André @quentinandre.bsky.social · 11/03/2025

Psych. Science just published a paper showing that the "warm glow" of donations can reduce depressive symptoms (d = [0.19, 0.46]). Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects. Big if true? Let's dive in.

57927

Craig Gedye @craiggedye.bsky.social · 09/03/2025

Note to anyone writing #clinicaltrial protocols: the word ‘subjects’ is pejorative and rude – people suffering illness may become patients of healthcare services, but transform themselves into participants when they volunteer to take part in clinical trials. Subjects are things we took at school.

161

Craig Gedye @craiggedye.bsky.social · 26/02/2025

There was messenger, transfer, ribosomal... then there was micro, then there was long non-coding, then circular, then MySpace, then Tumblr, Insta, Snapchat, TikTok... and then I gave up counting...

110

Craig Gedye @craiggedye.bsky.social · 23/02/2025

Send in the clones. Two papers in this week's @nature.com compare/contrast personalized neoantigen mRNA vaccines, with extraordinary success as adjuvant therapy in pancreatic cancer, but not helping when given late in lung cancer. Targeting ALL clones of each person's cancer is essential.

https://www.nature.com/articles/s41586-025-08586-y

https://www.nature.com/articles/s41586-024-08508-4

030

Craig Gedye @craiggedye.bsky.social · 22/02/2025

Take your chemo at night? Retrospective analysis of two large clinical trials suggests when you take temozolomide (am, pm, night) makes no difference in survival in #glioblastoma. Side effects might be better if taken at night. academic.oup.com/nop/advance-... @eortc.bsky.social

030

Reposted by Craig Gedye

Katie Coleman @katiekickscancer.bsky.social · 15/02/2025

Progress for chromophobe RCC at ASCO GU. Excited to check out the FOUR abstracts for #chRCC tomorrow (H31, H18, E21, E36) #chromophobe #GU25 @msaouel.bsky.social

093

Reposted by Craig Gedye

paulobergerot.bsky.social @paulobergerot.bsky.social · 02/12/2024

Integrating #ExerciseOncology into ICI tx Our study highlights feasibility & benefits of a remote & personalized program High adherence 81% & significant improvements in QOL, emotional sympts & side effects @crisbergerot.bsky.social @narjustflorezmd.bsky.social

0157

Reposted by Craig Gedye

Ian Davis @profiand.bsky.social · 13/02/2025

Beautiful presentation by Prof Louise Emmett of the @anzuptrials.bsky.social #ENZAp trial of enzalutamide +/- LuPSMA: ✅ Improved OS ✅ Improved quality of life Published today in Lancet Oncology www.thelancet.com/journals/lan...

Deterioration-free survival HR about 0.5

Conclusions;
Better OS in people at risk of poorer outcomes with enza alone
8mo OS benefit
Better QoL

274

Craig Gedye @craiggedye.bsky.social · 13/02/2025

Overall survival improved adding LuPSMA to enza in people with high risk prostate cancer, with almost 40% taking LuPSMA post study @anzuptrials.bsky.social @ascocancer.bsky.social #GU25

1104

Craig Gedye @craiggedye.bsky.social · 13/02/2025

Is there synergy, or just additive? Would be very grateful to see outcomes vs. subsequent therapy in the control arm, specifically those who did vs. did not take PARPi/platinum later…

100

Craig Gedye @craiggedye.bsky.social · 13/02/2025

Further data helping us personalise advanced prostate cancer treatment from a meta-analysis from @mrcnihrtmrp.bsky.social @ascocancer.bsky.social #GU25

042

Reposted by Craig Gedye

Carl T. Bergstrom @carlbergstrom.com · 04/02/2025

Modern-Day Oracles or Bullshit Machines? Jevin West (@jevinwest.bsky.social) and I have spent the last eight months developing the course on large language models (LLMs) that we think every college freshman needs to take. thebullshitmachines.com

thebullshitmachines.com

INTRODUCTION

17528061006

Reposted by Craig Gedye

Dr. Patrick Hwu @patrickhwumd.bsky.social · 01/02/2025

#ScienceSaturday 🧵 ➡️ Immunotherapies targeting neoantigens can be effective in mediating long-term durable responses in advanced cancer patients. However, identifying these neoantigens from metastatic tumors can be logistically challenging.

164

Craig Gedye @craiggedye.bsky.social · 31/01/2025

Resident medical officers play a vital role in the healthcare system, working at the frontline of acute inpatient hospital care alongside nursing and allied health staff. It's a stressful time and this kind of behaviour is completely unacceptable. www.theguardian.com/australia-ne...

theguardian.com

Australian hospital manager calls junior doctors ‘a workforce of clinical marshmellows’ in email stuff-up

Health officials rush to apologise as union calls misfired message from administrator ‘tone-deaf’ and ‘unacceptable’

010

Reposted by Craig Gedye

Dr Liz O’Riordan @lizoriordan.bsky.social · 30/01/2025

My new book ‘The Cancer Roadmap’ was launched today It’s for anyone affected by cancer It tells you what is it, what causes it, how it’s treated, who to trust, how to understand risk + spot red flags on social media when it comes to alternative cures. Get yours here lnk.to/TheCancerRoa...

311109135

Craig Gedye @craiggedye.bsky.social · 28/01/2025

PubMed down. Clinicaltrials.gov down too.

100